New Triple Antiviral Drug Combination Shows Early Promise For Treating COVID-19 In Phase 2 Randomized Trial

A two-week course of antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within 7 days of showing COVID-19 symptoms, is safe and more effective at reducing the duration of viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness, according to the first...